Clinical trial · Observational
Cd11b and Cd56 as Prognostic Markers in Acute Myeloid Leukemia
NCT03283228CI-TRIAL-00029544unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
1. Detect the expression of marker CD56 and CD11b in newly diagnosed cases of adult AML. 2. Study correlation between CD56 and CD11b expression with haematological parameters in cases of adult AML.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Adult Acute Myeloid Leukemia | Adult Acute Myeloid Leukemia | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Cd11b and Cd56 markers | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- CD11b and CD56 markers
- description
- Cd11b and Cd56 as Prognostic Markers in Acute Myeloid Leukemia
- interventionNames
- Diagnostic Test: Cd11b and Cd56 markers
- label
- Haematological parameters in cases of adult AML
- description
- Study correlation between CD56 and CD11b expression with haematological parameters in cases of adult AML
- interventionNames
- Diagnostic Test: Cd11b and Cd56 markers
Primary outcomes (1)
- measure
- CD11b and CD56 marker
- timeFrame
- 24 month
- description
- Detect the expression of marker CD56 and CD11b in newly diagnosed cases of adult AML.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 50 Years
Show eligibility criteria text
Inclusion Criteria: Anew diagnosis cases of adult AML Exclusion Criteria: 1. Pediatric AML . 2. follow up cases of adult AML
References
Publications (0)
Data not yet available
No reference posted for this study.